Core Insights - The article discusses the transformation of waste cooking oil into clean biodiesel in Chongqing, highlighting the city's efforts in building a "waste-free city" model focused on efficient waste disposal and resource recycling [1][2]. Group 1: Waste Management Initiatives - Chongqing has been a pilot city for the "waste-free city" initiative since 2019, promoting effective resource recycling and waste reduction [1]. - The "venous industry" concept is introduced, which focuses on waste recycling and resource re-utilization, addressing the issues of waste surplus and resource scarcity [2]. - The Chongqing Electric Power Resource Recycling Center has successfully dismantled over 7,000 transformers and 6,000 tons of cables, producing over 25,000 tons of high-quality recycled resources [3]. Group 2: Community Engagement and Technology - The implementation of smart recycling devices in residential areas has made waste sorting more convenient, encouraging community participation in recycling efforts [4][5]. - The city has established a comprehensive waste management system that integrates waste disposal and recycling, enhancing operational efficiency [5]. Group 3: Cross-Provincial Collaboration - A cross-provincial cooperation mechanism for hazardous waste management has been established between Sichuan and Chongqing, streamlining the approval process for hazardous waste transfer [6][7]. - The collaboration has expanded to include nine categories of hazardous waste, improving disposal efficiency for companies like Zinc Light [6][7].

一锅翻腾的重庆红油火锅，食客享用后，油去哪儿了？ 答案就藏在餐饮废油处置车间里。每天清晨，印有"厨余垃圾"标识的重庆市环卫集团专用运输车驶入两 江新区洛碛"静脉产业园"，将餐厨垃圾运送至车间。经过处理后，分离出的废弃油脂将被转化为清洁的 生物柴油，供给下游工业企业。 红油的变废为宝，正是重庆市建设"无废城市"的一个缩影。 "无废城市"，并非指城市完全不产生废弃物，而是以废弃物的安全高效处置、资源循环利用和减少废弃 物产生为重点的发展模式。自2019年入选全国首批"无废城市"建设试点以来，重庆深入推进"无废城 市"建设，有效推动资源再生利用。近日，记者深入园区工厂、街道社区等，了解重庆市的探索成效。 "静脉产业园"助力废弃物循环利用 走进重庆永川港桥"静脉产业园"，重庆电力再生资源循环利用中心的厂房内，工作人员正全神贯注地对 一台35千伏油浸式变压器进行吊芯作业。待铁芯与油箱完全分离后，重达数吨的铁芯被移至拆解平台。 "分离出来的液体叫变压器油，属于危险废物，若是随意处置或处置不当，不仅会污染土壤，更会对地 下水造成难以逆转的破坏。"中心现场负责人王开才说。 重庆电力再生资源循环利用中心成立后，努力破解废旧电力 ...

Core Viewpoint - *ST Bio (000504) expects significant revenue growth in 2025, projecting operating income between 385 million to 425 million yuan, compared to approximately 130 million yuan in the previous year, indicating a substantial year-on-year increase [2][5]. Financial Performance - The company anticipates a total profit of 18.5 million to 26.5 million yuan for 2025, with net profit attributable to shareholders expected to be between 28.5 million to 32.5 million yuan, and net profit after deducting non-recurring gains and losses projected at 8.5 million to 12.5 million yuan, all indicating a turnaround from previous losses [2][5]. - Basic earnings per share are forecasted to be between 0.025 yuan and 0.037 yuan, a recovery from a loss of 0.06 yuan per share in the previous year [5]. Revenue Drivers - The revenue increase is attributed to the acquisition of Loudi Jinhong New Materials Co., which enhanced the company's recycling business, particularly in the areas of waste battery and scrap steel recycling [5][6]. - The company has also expanded sales of related products in its main business, including beauty and health products linked to its biopharmaceutical operations, contributing to revenue and profit growth [5][6]. Cost Management - In 2025, *ST Bio implemented cost reduction and efficiency improvement measures, including organizational restructuring, personnel optimization, and expense control, which enhanced profitability [6]. Regulatory Context - 2025 is a critical year for *ST Bio to avoid delisting, as the company faced a risk warning due to negative profits and revenue below 300 million yuan in 2024 [7]. - The company can apply to lift the delisting risk warning if it meets specific financial criteria in the subsequent annual report [7]. Asset Restructuring - Concurrently, *ST Bio announced the termination of a major asset restructuring plan aimed at acquiring a 51% stake in Hunan Huize Biopharmaceutical Technology Co., a professional CRO company [11][12].

突发公告，终止筹划重大资产重组。 *ST生物（000504）1月22日晚间公告，公司于2025年8月12日披露了《关于筹划重大资产重组暨签署股 权收购意向协议的提示性公告》，拟收购程泽能、易木林、长沙君合致远企业管理咨询合伙企业（有限 合伙）、长沙市履方医药信息咨询合伙企业（有限合伙）合计持有的湖南慧泽生物医药科技有限公司 51%股权。本次筹划重组事项尚未进入正式实施阶段，交易各方未达成实质性协议，2026年1月22日公 司与交易各方签署了《股权收购意向协议之终止协议》。 公告称，自筹划重大资产重组事项以来，公司按照相关法律法规要求，积极推进本次重大资产重组的各 项工作。交易各方对本次重大资产重组交易方案进行了多次协商和谈判，未能最终达成一致。为切实维 护公司及全体股东利益，经公司审慎研究，并与交易各方友好协商，交易各方一致同意终止筹划本次交 易。 *ST生物称，终止本次交易系公司与相关各方经充分沟通、审慎分析及友好协商后作出的决定，各方就 本次交易终止无需承担任何违约责任。本次重大资产重组的终止，不会对公司现有生产经营活动、财务 状况产生重大不利影响。目前公司生产经营秩序正常，本次交易的终止不存在损害公司及 ...

突发公告，终止筹划重大资产重组。 *ST生物（000504）1月22日晚间公告，公司于2025年8月12日披露了《关于筹划重大资产重组暨签署股 权收购意向协议的提示性公告》，拟收购程泽能、易木林、长沙君合致远企业管理咨询合伙企业（有限 合伙）、长沙市履方医药信息咨询合伙企业（有限合伙）合计持有的湖南慧泽生物医药科技有限公司 51%股权。本次筹划重组事项尚未进入正式实施阶段，交易各方未达成实质性协议，2026年1月22日公 司与交易各方签署了《股权收购意向协议之终止协议》。 公告称，自筹划重大资产重组事项以来，公司按照相关法律法规要求，积极推进本次重大资产重组的各 项工作。交易各方对本次重大资产重组交易方案进行了多次协商和谈判，未能最终达成一致。为切实维 护公司及全体股东利益，经公司审慎研究，并与交易各方友好协商，交易各方一致同意终止筹划本次交 易。 *ST生物称，终止本次交易系公司与相关各方经充分沟通、审慎分析及友好协商后作出的决定，各方就 本次交易终止无需承担任何违约责任。本次重大资产重组的终止，不会对公司现有生产经营活动、财务 状况产生重大不利影响。目前公司生产经营秩序正常，本次交易的终止不存在损害公司及 ...

Core Viewpoint - *ST Bio's major asset restructuring plan has failed, leading to the termination of the agreement to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. [1][6] Group 1: Restructuring Details - On January 22, 2026, *ST Bio signed a termination agreement for the acquisition of Hunan Huize Biomedical Technology Co., Ltd. [1][6] - The restructuring plan was initially announced on August 12, 2025, but did not progress to formal implementation due to a lack of substantial agreements among the parties involved [1][6][10] - The failure of the restructuring was attributed to unsuccessful negotiations and a lack of consensus among the transaction parties [10] Group 2: Company Background and Operations - *ST Bio primarily operates in the "biomedical" and "energy-saving and environmental protection" sectors, focusing on the production and sales of related products [3][8] - The company aims to enhance its profitability and risk resistance through the acquisition of Huize Biomedical, which specializes in drug research and clinical evaluation services [3][8] - Huize Biomedical has established long-term partnerships with over 300 pharmaceutical companies and research institutions, completing more than 1,000 technical service projects [3][8] Group 3: Financial Performance - *ST Bio has forecasted a net profit attributable to shareholders of 28.5 million to 32.5 million yuan for 2025, a significant recovery from a loss of 19.846 million yuan in the previous year [4][10] - The company has expanded its operations by acquiring and controlling Loudi Jinhong New Materials Co., Ltd., which has significantly boosted its revenue from recycling businesses [5][10] - The company has also diversified its product offerings, including sales of beauty and health products related to its biomedical business, contributing to revenue and profit growth [5][10]

格隆汇1月22日丨*ST生物（维权）(000504.SZ)公布，预计2025年归属于上市公司股东的净利润2,850万 元–3,250万元，同比扭亏为盈，扣除非经常性损益后的净利润850万元–1,250万元，同比扭亏为盈，营业 收入38,500万元–42,500万元。 1.报告期公司并购并控股了娄底金弘新材料有限公司，进一步丰富了再生资源业务内容，废旧动力电 池、废钢等资源再生利用回收业务大幅度提升了公司收入水平。2.报告期公司大力拓展主营业务相关衍 生产品的销售，包括生物医药业务相关的美妆产品和保健品销售、环保业务相关的产品销售等，带动了 收入和利润的增长。3.报告期公司通过组织架构精简、人员优化、费用管控等降本增效措施，提升了盈 利能力。4.报告期收到的政府补助同比上年增加。 ...

格隆汇1月19日丨超越科技(301049.SZ)公布，公司于近日收到安徽省工业和信息化厅、安徽省财政厅、 国家税务总局安徽省税务局联合颁布的高新技术企业证书，通过了高新技术企业重新认定，证书编号： GR202534000464，发证日期为2025年10月28日。本次高新技术企业的认定系公司原高新技术企业证书 有效期满所进行的重新认定，根据《中华人民共和国企业所得税法》及国家对高新技术企业的相关税收 政策规定，公司自通过高新技术企业认定起连续三年可继续享受国家关于高新技术企业的相关税收优惠 政策，即按15%的税率缴纳企业所得税。 ...

中再资环公告，公司财务部门初步测算，预计2025年度归属于上市公司股东的净利润为负值，公司2025 年度经营业绩将出现亏损。公司已就本次业绩预告事项与年审会计师进行了预先沟通，双方不存在重大 分歧。2025年度公司业绩出现亏损，主要受行业政策调整、市场环境变化等因素影响。 ...

证券日报网讯 1月7日，华新环保在互动平台回答投资者提问时表示，再生阴极铜项目目前处于工程建 设阶段，公司全力保障项目安全、质量与进度，为后续投产奠定基础。贵金属回收项目目前处于产能爬 坡与工艺优化阶段，已实现部分产出。公司致力于提升产线运行效率、产品收率及稳定性。项目的财务 数据请关注公司后续的定期报告披露。 （文章来源：证券日报） ...